Article info
PDFClinical trial
A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030)
- Correspondence to Professor Ana Oaknin, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain; aoaknin{at}vhio.net
Citation
A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030)
Publication history
- Accepted September 24, 2019
- First published October 23, 2019.
Article Versions
- You are currently viewing a Previous version of this article (23 October 2019).
- View the most recent version of this article
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.